Monoclonal Antibodies (Woomera Therapeutics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameMonoclonal Antibodies (Woomera Therapeutics)
Drug Alias NameAbner (Woomera Therapeutics)
ClassificationRadiation-emitting productsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVasopressin V2 receptor antagonists
TargetsVasopressin V2 receptor
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWoomera Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWoomera Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSmall Cell Lung Carcinoma

Other Information

ATC CodeN/A
Related LinksN/A